👆👇 #HeartFailureDays
#HeartFailureWeek

#DICTATE_AHF

#SGLT2i in #AcuteHF confirmed multiple clinical benefits without Adverse Events

🍀 On-top of SGLT2i ⬇️ of ☠️

The 1st choice to decongest & ⬆️ survival of our #HF patients

#Findme

bit.ly/4dmoGgc

American College of Cardiology

Thanks to the chief editor Maciej Banach and all coauthors that you may meet at #EASCongress2024 ☀️

#EHJPharmacotherapy 💊
EHJ-CVP Editor-in-Chief
European Society of Cardiology Journals

#CardioTwitter

Factor XIa inhibitors: collecting the clinical evidence 📚⤵️
academic.oup.com/ehjcvp/article…

#Pharmapulse 🔥
#EHJPharmacotherapy 💊
EHJ-CVP Editor-in-Chief 👨‍💼
European Society of Cardiology Journals European Society of Cardiology 📣
#CardioTwitter #Cardiology

#cardiology #cardiotwitter #cardiovascular #cardioX JACC Journals

✅ Safety of #alirocumab is indistinguishable from #placebo except for ∼2% risk in injection-site reactions. New insights from 47,296 patient-years of observation just published in #EHJPharmacotherapy 💊⤵️
tinyurl.com/alirocumab

EHJ-CVP Editor-in-Chief Dr. Deepak L. Bhatt European Society of Cardiology
#openaccess

✅ Safety of #alirocumab is indistinguishable from #placebo except for ∼2% risk in injection-site reactions. New insights from 47,296 patient-years of observation just published in #EHJPharmacotherapy 💊⤵️
tinyurl.com/alirocumab

EHJ-CVP Editor-in-Chief Dr. Deepak L. Bhatt European Society of Cardiology
#openaccess

In Episode 9 of our Understanding INOCA series, we welcome INOCA International Medical Advisory Board member, Sister Ashley Davidson discussing Cardiac Rehab and INOCA! 😃

You can enjoy the full video presentation here -
inocainternational.com/video-presenta…

Ischemic stroke in #women with #AFib : temporal trends and clinical implications EHJ Editor-in-Chief 📚
academic.oup.com/eurheartj/arti…

#CardioTwitter #CardioEd European Society of Cardiology Journals

Clopidogrel monotherapy was associated with a lower rate of a primary composite end point of all-cause death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and major bleeding compared to aspirin monotherapy as long-term maintenance therapy

#CardioTwitter 🔥

GLP-1 RA use & association w/ outcomes in patients w/ #HF & #T2DM : new data from the Swedish HF & Swedish National Diabetes Registries 🇸🇪 now published w/ #openaccess in #EHJPharmacotherapy 👉 bit.ly/3vUqH2l

Felice Gragnano EHJ-CVP Editor-in-Chief Gianluigi Savarese Karolinska Institutet

🚑 Le Linee Guida #ESC 2023 sulle ACS assumono una posizione contraria all'utilizzo 'routinario' del pre-trattamento con P2Y12-I, anche nello #STEMI . Cosa cambia per la nostra pratica? ⤵️

✅ atbv.it/pre-trattament…

ATBV CardioInfo CardioLink Scientific News

#CardioTwitter

#CardioTwitter #Cardiology
#EHJPharmacotherapy 💊

Patients with coronary aneurysms and coronary dilation: is it the time for genetic testing?

#EHJ #cardiotwitter European Society of Cardiology Journals European Society of Cardiology
#gene #pathogenic #variants #coronary #aneurysms

academic.oup.com/eurheartj/adva…

Contemporary American and European heart failure guidelines jacc.org/doi/abs/10.101… JACC Journals

This Expert Review:
✅Addresses the rationale for left ventriculoplasty.
✅Presents previous surgical and percutaneous attempts in the field.
✅Provides an overview of novel transcatheter left ventriculoplasty devices and their respective trials.
✅Highlights potential challenges

🚨Stunning!🚨

REVERSAL in the decline of heart failure ☠️ in the US 1999-2021

1999-2005 ⬇️ ☠️
2005-2012 ⬇️ ☠️
2012-2019 ⬆️ ☠️
2019-2021 ⬆️⬆️☠️

Age-adjusted HF related ☠️ rates higher in 2021 vs 1999!

WT😱🆘

jamanetwork.com/journals/jamac…

JAMA Cardiology Marat Fudim, MD MHS

#ESCPrev2024
Severe obesity-one size fits all?
See all sessions on this topic!

Unresolved issues
✅ DOAC pharmacokinetics are skewed in pts >120kg, BMI>40kg/m2
✅ Uncertainty regarding DOAC use, selection, dose adjustment in such pts
✅More data needed!
👉ncbi.nlm.nih.gov/pmc/articles/P…

In this large, real-world study, GLP-1 RA use was not associated with a higher risk of HHF/CV death but with longer survival and less major CV adverse in patients with HF and T2DM
academic.oup.com/ehjcvp/article…
EHJ-CVP Editor-in-Chief Stefan Agewall Felice Gragnano